



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



SP-13786

Item No. 41857

CAS Registry No.: 1448440-52-5
Formal Name: N-[2-[(2S)-2-cyano-4,4-difluoro-1-pyrrolidiny]-2-oxoethyl]-4-quinolinecarboxamide
Synonym: UAMC-1110
MF: C₁₇H₁₄F₂N₄O₂
FW: 344.3
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SP-13786 is supplied as a solid. A stock solution may be made by dissolving the SP-13786 in the solvent of choice, which should be purged with an inert gas. SP-13786 is sparingly soluble (1-10 mg/ml) in ethanol and soluble (≥10 mg/ml) in DMSO.

Description

SP-13786 is an inhibitor of the protease fibroblast activation protein (FAP; IC₅₀ = 3.2 nM).¹ It is selective for FAP over prolyl endopeptidase, dipeptidyl peptidase 4 (DPP-4), DPP-9, and DPP-2 (IC₅₀s = >1.8, >100, >12.5, and >100 μM, respectively). Nanoliposomes containing a PEGylated form of SP-13786 have been used to target cancer-associated fibroblasts (CAFs) *in vitro* and *in vivo*.²

References

1. Jansen, K., Heirbaut, L., Verkerk, R., *et al.* Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). *J. Med. Chem.* **57(7)**, 3053-3074 (2014).
2. Kong, L., Yu, Y., Yang, R., *et al.* Development and efficacy evaluation of nanoliposomes targeting CAFs-LCSCs communication for hepatocellular carcinoma treatment. *Chem. Eng. J.* **496**, 154173 (2024).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/09/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM